Filter Releases
 
News Releases
Date Title and Summary View
Jan 4, 2012
Montreal, Quebec. January 4, 2012 – MethylGene Inc. (TSX: MYG) today announced the appointment of Rachel Humphrey, MD, to the post of Executive Vice President and Chief Medical Officer. Dr. Humphrey is board certified in Medical Oncology and has led the development of multiple oncology agents, two of which are currently commerciali...
Feb 2, 2012
Montreal, Quebec. February 2, 2012 – MethylGene Inc. (TSX: MYG) is pleased to announce the appointment of Dr. Henry J. Fuchs to the Company’s Board of Directors. “Dr. Fuchs is a highly regarded leader in the biotechnology industry and brings a wealth of drug development and management experience at public life science ...
Feb 7, 2012
Montreal, Canada.  February 7, 2012 – MethylGene Inc. (TSX: MYG) announced today that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present a corporate overview of the Company on Monday, February 13 at 4:30 p.m. EST, at the 14th Annual BIO CEO & Investor Conference. The event is being held at the Wa...
Mar 15, 2012
Montreal, Quebec.  March 15, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the fourth quarter and full year ended December 31, 2011. Highlights During the fourth quarter we commenced our first randomized, controlled Phase 2 study with MGCD290, and our two Phase 1 dose escalation ...
Mar 19, 2012
Montreal, Quebec. March 19, 2012 – MethylGene Inc. (TSX: MYG) today announced the appointment of Peggy Mulligan, FCA to the Company’s Board of Directors. “Peggy is a financial and audit expert, and a well respected business leader. We look forward to her guidance as we plan for the future”, said Charles Grubsztajn, Pre...
Mar 28, 2012
Montreal, Quebec. March 28, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its multi-targeted kinase inhibitor, MGCD265, will be reported in a poster session at the 2012 American Association for Cancer Research (AACR) Annual Meeting to be held in Chicago, Illinois from March 31 to A...
Apr 2, 2012
Montreal, Canada. April 2, 2012 – MethylGene Inc. (TSX:MYG) today disclosed preclinical data during a presentation for its proprietary multi-targeted kinase inhibitor, MGCD265, at the 2012 AACR Annual Meeting held in Chicago, Illinois. Results were presented showing the potent inhibition of tumor growth ...
May 14, 2012
Montreal, Canada.  May 14, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the first quarter ended March 31, 2012 and provided an update on clinical programs.  Highlights  Rachel W. Humphrey, MD was appointed as Executive Vice President and Chief...
May 23, 2012
Montreal, Canada. May 23, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Joseph Walewicz, Vice President, Business and Corporate Development, will present an overview of the Company at the BioFinance 2012 Conference which will be held at the St. Andrew’s Club & Conference Centre in Toronto. Mr. Walewicz will be pres...
May 29, 2012
Montreal, Canada. May 29, 2012 – MethylGene Inc. (TSX:MYG) today announced that clinical data for its Met/VEGF-R kinase inhibitor, MGCD265, will be presented at the 2012 ASCO Annual Meeting to be held in Chicago, Illinois from June 1 to 5, 2012. This poster presentation will highlight the safety profile of MGC...
Jun 4, 2012
Montreal, Canada. June 4, 2012 – MethylGene Inc. (TSX:MYG) today announced that clinical data for its Met/VEGFR multi- kinase inhibitor MGCD265 was presented in a poster session at the 2012 ASCO Annual Meeting held in Chicago, Illinois. The poster, entitled “MGCD265, a multitargeted oral tyrosine kinase recept...
Jun 14, 2012
Montreal, Canada. June 14, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present an overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference which will be held at the Toronto Board of Trade on Thursday, June 21,...
Jun 27, 2012
Montreal, Canada. June 27, 2012 – MethylGene Inc. (TSX: MYG) today announced the election of Rodney Lappe, Ph.D., to the Company’s Board of Directors at the Company’s annual meeting of shareholders held earlier today.   “Over the past year we have significantly enhanced our management team while adding four industry le...
Jul 9, 2012
Montreal, Canada. July 9, 2012 – MethylGene Inc. (TSX:MYG) today announced that Mr. Charles Grubsztajn, President and Chief Executive Officer, will present an overview of the Company at the Seventh Annual JMP Securities Healthcare Conference which will be held at The Peninsula New York Hotel, New York City. Mr...
Aug 2, 2012
Montreal, Canada. August 2, 2012 – MethylGene Inc. (TSX: MYG) today reported financial results for the second quarter ended June 30, 2012 and provided an update on its clinical programs. Highlights As of August 1st, over one third of the patients have been enrolled in the first Phase II tria...
Page:
...
Next Last
 
= add release to Briefcase